RePORT International Resources

Learn how to analyse, interpret, and present routine TB surveillance data and how to make use of your findings to generate hypotheses for further investigation and planning programmatic responses. This course draws on basic principles of epidemiology which are applied to TB surveillance data, also covered in the Understanding and using tuberculosis data handbook. Learners should also consult the Consolidated guidance on tuberculosis data generation and use: module 1: tuberculosis surveillance for an up-to-date set of recommendations. Examples, practice exercises and case studies are based on reported findings from conducting national TB epidemiological reviews which follow a standardized terms of reference, implementation methodology and analytical plan.

Learn how to analyse, interpret, and present routine TB surveillance data and how to make use of your findings to generate hypotheses for further investigation and planning programmatic responses. This course draws on basic principles of epidemiology which are applied to TB surveillance data, also covered in the Understanding and using tuberculosis data handbook. Learners should also consult the Consolidated guidance on tuberculosis data generation and use: module 1: tuberculosis surveillance for an up-to-date set of recommendations. Examples, practice exercises and case studies are based on reported findings from conducting national TB epidemiological reviews which follow a standardized terms of reference, implementation methodology and analytical plan.

Learn how material support can boost TB treatment adherence by reducing economic barriers like transport or medication costs. This module explores practical aid strategies, needs assessment, and building partnerships to support people with TB. Participants should have a general understanding of TB as a disease, including its symptoms, transmission, treatment and social support. Basic experience in working with people affected by TB or other health conditions, especially in community or social support settings, is helpful. No advanced medical knowledge is required, but familiarity with patient interaction and service delivery will support better understanding of the course content.

The World Health Organization (WHO), in collaboration with the TB Europe Coalition (TBEC) convened a global webinar on the operationalization of WHO‚ Multisectoral Accountability Framework to End TB (MAF-TB). This webinar showcased how countries and partners are translating the MAF-TB into practice, transforming commitments into concrete actions to drive accountability and accelerate progress towards ending TB.

The World Health Organization (WHO), in collaboration with the TB Europe Coalition, is hosting a series of international #EndTB webinars dedicated to advancing the implementation of the Multisectoral Accountability Framework to End TB (MAF-TB). The series serves as an interactive platform for countries and partners to exchange experiences, share best practices, and discuss practical approaches to operationalizing MAF-TB at national and regional levels. The second special session focused on catalysing action to address the social determinants and key drivers of TB through the implementation of MAF-TB. It highlighted how strengthened collaboration across the social protection, labour, justice, and nutrition sectors can accelerate progress towards ending TB.

This website provides access to the latest WHO recommendations on all aspects of tuberculosis prevention and care. The user can search, filter and cross-tabulate the recommendations through built-in functions. For each individual recommendation one can also access key background information, such as the evidence summaries and the Guideline Development Group decisions underpinning it.

This call to action accompanies the consensus statement on the optimal and early inclusion of pregnant and lactating women in tuberculosis research and specifies the actions that need to be taken to ensure full implementation of the agreed approaches in the statement. The target audience includes product developers and industry, study sponsors, funding agencies, researchers and research networks, regulatory authorities, institutional review boards (IRBs) and ethics committees, national TB and maternal and child health programmes, civil society organizations and affected communities, and health care providers.

This WHO training kit helps manufacturers and regulators, especially in low- and middle-income countries, learn how to produce safe, effective, and high-quality vaccines, medicines, and diagnostic tests. It compiles expert-reviewed Q&As from the “Week of Quality” training on quality standards, regulatory compliance, and product development, serving as a reference for strengthening local production.

The Guidance on evidence generation (GEG) on new regimens for tuberculosis treatment is a first-of-its-kind document that advises researchers, developers, funders, and other stakeholders about how evidence should be generated to optimally inform WHO guideline development on novel regimens for TB treatment. It outlines 21 key messages, explains why they are important, and what approaches can increase the chances of research leading to strong WHO recommendations. The key messages cover areas such as trial design, selection criteria, outcome choice, sample size, analytic and economic considerations, and how to Investigate the impact of an intervention on health equity, acceptability, and feasibility. The evidence available to WHO for use in guideline development has often presented challenges that have limited the strength of recommendations and their applicability to certain population groups or have meant that the evidence is not suitable for policy development. The reasons for these challenges are addressable but are not always well understood by all stakeholders. The guidance provided in the GEG document should allow those who aim to influence policy to design trials and other studies in a way that maximizes the potential to do so.

In 2024, the WHO Global Programme on Tuberculosis & Lung Health led a consensus building process to advance the earlier and optimal inclusion of pregnant women in TB research. The process is aligned with broader global developments to transform clinical trial practices, including addressing the needs of underrepresented populations. This consensus statement summarizes the consensus process, which included five thematic working groups (covering preclinical TB research, TB therapeutics research, TB vaccine research, maternal TB surveillance systems and advocacy), evidence reviews to address gaps in data and knowledge and a consensus meeting in February 2025. The approaches to earlier and optimal inclusion arising from the consensus process include crosscutting actions as well as approaches specific to each working group theme.

The WHO TB Patient Cost Survey resources include a standardized household questionnaire (2025 version) for collecting data on the economic impact of TB, along with companion STATA datasets and code to support data entry, management, and analysis. These tools are designed to promote consistent methodology and facilitate cross-country comparisons in TB research and program evaluation.

The WHO TB Patient Cost Survey resources include a standardized household questionnaire (2025 version) for collecting data on the economic impact of TB, along with companion STATA datasets and code to support data entry, management, and analysis. These tools are designed to promote consistent methodology and facilitate cross-country comparisons in TB research and program evaluation.

The new WHO TPPs for TB screening tests were developed after an extensive consultation of a large cross section of constituencies. They provide manufacturers and other stakeholders in research and development with the latest product- and technology-agnostic guidance that encompass all possible approaches used for TB screening.